Biologic and molecular effects of granulocyte colony-stimulating factor in healthy individuals: Recent findings and current challenges

Blood

Volumn 111, Issue 4, 2008, Pages 1767-1772

  Anderlini, Paolo ^a   Champlin, Richard E ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE COLONY STIMULATING FACTOR RECEPTOR; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR;

ALLOGENEIC STEM CELL TRANSPLANTATION; BONE MARROW CELL; CELL LINEAGE; CELL TYPE; CHROMOSOME; GRANULOCYTE TRANSFUSION; HUMAN; IMMUNOMODULATION; LYMPHOCYTE; PERIPHERAL BLOOD STEM CELL; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SAFETY;

EID: 41349110208     PISSN: 00064971     EISSN: 00064971     Source Type: Journal    
DOI: 10.1182/blood-2007-07-097543     Document Type: Review

References (64)

1. Anderlini P, Przepiorka D, Champlin R, Körbling M. Biologic and clinical effects of granulocyte colony-stimulating factor in normal individuals. Blood. 1996;88:2819-2825.
2. Russell N, Gratwohl A, Schmitz N. The place of blood stem cells in allogeneic transplantation. Br J Haematol. 1996;93:747-53.
3. Horowitz MM, Confer DL. Evaluation of hematopoietic stem cell donors. In: Berliner N, Lee SJ, Linenberger M, Vogelsang GB, eds. Hematology 2005, American Society of Hematology Education Program Book; 2005:469-475.
4. Price TH. Granulocyte transfusion therapy: it's time for an answer. Transfusion. 2006;46:1-5.
5. McSweeney PA, Niederwieser D, Shizuru JA, et al. Hematopoietic cell transplantation in older patients with hematologic malignancies: replacing high-dose cytotoxic therapy with graft-versus-tumor effects. Blood. 2001;97:3390-3400.
6. Cincotta R, Balloch A, Metz J, Layton JE, Lieschke GJ. Physiological neutrophilia of pregnancy is not associated with a rise in plasma granulocyte colony-stimulating factor (G-CSF)[letter]. Am J Hematol. 1995;48:288
7. Kawakami M, Tsutsumi H, Kumakawa T, et al. Levels of granulocyte colony-stimulating factor in patients with infections. Blood. 1990;76:1962-1964.
8. de Haas M, Kerst JM, van der Schoot C, et al. Granulocyte colony-stimulating factor administration to healthy volunteers: analysis of the immediate activating effect on circulating neutrophils. Blood. 1994;84:3885-3894.
9. Pauksen K, Elfman L, Ulfgren AK, Venge P: Serum levels of granulocyte colony-stimulating factor (G-CSF) in bacterial and viral infections, and in atypical pneumonia. Br J Haematol. 1994;88:256-260.
10. Barth E, Fischer G, Schneider EM, Moldawer LL, Georgieff M, Weiss M. Peaks of endogenous GCSF serum concentrations are followed by an increase in respiratory burst activity of granulocytes in patients with septic shock. Cytokine. 2002;17:275-284.
11. Hernández-Bernal F, García-García I, González-Delgado CA, et al. Bioequivalence of two recombinant granulocyte colony-stimulating factor formulations in healthy male volunteers. Biopharm Drug Dispos. 2005;26:151-159.
12. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor Blood. 1991;78:2791-2808.
13. Avalos BR: Molecular analysis of the granulocyte colony-stimulating factor receptor. Blood. 1996;88:761-777.
14. Boneberg EM, Hareng L, Gantner F, Wendel A, Hartung T. Human monocytes express functional receptors for granulocyte colony- stimulating factor that mediate suppression of monokines and interferon-γ. Blood. 2000;95:270-276.
15. Franzke A, Piao W, Lauber J, et al. G-CSF as immune regulator in T cells expressing the G-CSF receptor: implications for transplantation and autoimmune disease. Blood. 2003;102:734-739.
16. Shimoda K, Okamura S, Harada N, Kondo S, Okamura T, Niho Y. Identification of a functional receptor for granulocyte colony-stimulating factor on platelets. J Clin Invest. 1993;91:1310-1313.
17. Solaroglu I, Cahill J, Jadhav V, Zhang JH. A novel neuroprotectant granulocyte-colony stimulating factor. Stroke. 2006;37:1123-1128.
18. Newburger PE. Disorders of neutrophil number and function. In: Berliner N, Linker C, Schiffer CA, eds. Hematology 2006, American Society of Hematology Education Program Book; 2006:104-110.
19. Berliner N, Horwitz M, Loughran Jr TP. Congenital and acquired neutropenia. In: Broudy VC, Berliner N, Larson RA, Leung LL, eds. Hematology 2004, American Society of Hematology Education Program Book; 2004:63-79.
20. Dong F, Brynes RK, Tidow N, et al. Mutations in the gene for the granulocyte-colony-stimulating factor receptor in patients with acute myeloid leukemia preceded by severe congenital neutropenia. N Engl J Med. 1995;333:487-493.
21. Dong F, Dale DC, Bonilla MA, et al. Mutations in the granulocyte colony-stimulating factor receptor gene in patients with severe congenital neutropenia. Leukemia. 1997;11:120-125.
22. Naparstek E. Granulocyte colony-stimulating factor, congenital neutropenia and acute myeloid leukemia. N Engl J Med. 1995;333:516-518.
23. Falanga A, Marchetti M, Evangelista V, et al. Neutrophil activation and hemostatic changes in healthy donors receiving granulocyte colony-stimulating factor. Blood. 1999;93:2506-2514.
24. Ohsaka A, Saionji K, Kuwaki T, Takeshima T, Igari J. Granulocyte colony-stimulating factor administration modulates the surface expression of effector cells molecules on human monocytes. Br J Haematol. 1995;89:465-472.
25. Mielcarek M, Graf L, Johnson G, Torok-Storb B. Production of interleukin-10 by granulocyte colony-stimulating factor-mobilized blood products: a mechanism for monocyte-mediated suppression of T-cell proliferation. Blood. 1998;92:215-222.
26. Fraser AR, Cook G, Franklin IM, et al. Immature monocytes from G-CSF-mobilized peripheral blood stem cell collections carry surface-bound IL-10 and have the potential to modulate alloreactivity. J Leukoc Biol. 2006;80:862-869.
27. Shimoda K, Okamura S, Inaba S, et al. Granulocyte colony-stimulating factor and platelet aggregation [letter]. Lancet. 1993;341:633
28. Avenarius HJ, Freund M, Deinhardt J, Poliwoda H. Effect of recombinant human granulocyte colony-stimulating factor (rhG-CSF) on circulating platelets. Ann Hematol. 1992;65:6-9.
29. LeBlanc R, Roy J, Demers C, Vu L, Cantin G. A prospective study of G-CSF effects on hemostasis in allogeneic blood stem cell donors. Bone Marrow Transplant. 1999;23:991-996.
30. Topcuoglu P, Arat M, Dalva K, Ozcan M. Administration of granulocyte-colony-stimulating factor for allogeneic hematopoietic cell collection may induce the tissue factor-dependent pathway in healthy donors. Bone Marrow Transplant. 2004;33:171-176.
31. Söhngen D, Wienen S, Siebler M, et al. Analysis of rhG-CSF-effects on platelets by in vitro bleeding test and transcranial Doppler ultrasound examination. Bone Marrow Transplant. 1998;22:1087-1090.
32. Tigue CC, McKoy AMEvens Trifilio SM, Tallman MS, Bennett CL. Granulocyte-colony stimulating factor administration to healthy individuals and persons with chronic neutropenia or cancer: an overview of safety considerations from the Research on Adverse Drug Events and Reports project. Bone Marrow Transplant. 2007;40:185-192.
33. Hill JM, Syed MA, Arai AE, et al. Outcomes and risks of granulocyte colony-stimulating factor in patients with coronary artery disease. J Am Coll Cardiol. 2005;46:1643-1648.
34. Kang H, Kim H, Zhang S, et al. Effects of intracoronary infusion of peripheral blood stem-cells mobilized with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomized clinical trial. Lancet. 2004;363:751-756.
35. Zohlnhöfer D, Ott I, Mehilli J, et al. Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA. 2006;295:1003-1010.
36. Kusnierz-Glaz CR, Still BJ, Amano M, et al. Granulocyte colony-stimulating factor-induced comobilization of CD4-CD8- T-Cells and hematopoietic progenitor cells (CD34+) in the blood of normal donors. Blood. 1997;89:2586-2595.
37. Rutella S, Zavala F, Danese S, Kared H, Leone G. Granulocyte colony-stimulating factor: a novel mediator of T-cell tolerance. J Immunol. 2005;175:7085-7091.
38. Lindemann M, Rebmann V, Ottinger H, Schmolke K, Kreuzfelder E, Grosse-Wilde H. rhG-CSF effect on mixed lymphocyte cultures and circulating soluble HLA antigen levels in volunteer stem cell donors. Exp Hematol. 2004;32:1103-1109.
39. Morris ES, MacDonald KPA, Rowe V, et al. Donor treatment with pegylated G-CSF augments the generation of IL-10-producing regulatory T cells and promotes transplantation tolerance. Blood. 2004;103:3573-3581.
40. Rutella S, Rumi C., Pierelli L, et al. Granulocyte colony-stimulating factor perturbs lymphocyte mitochondrial function and inhibits cell cycle progression. Exp Hematol. 2000;28:612-625.
41. Lassailly F, Sielleur I, Blaise D, Chabannon C. rhG-CSF does not affect the phenotype of adult donor peripheral blood NK cells. Bone Marrow Transplant. 2005;35:25-32.
42. Weiss M, Moldawer LL, Schneider EM. Granulocyte colony-stimulating factor to prevent the progression of systemic nonresponsiveness in systemic inflammatory response syndrome and sepsis. Blood. 1999;93:425-439.
43. Watanabe T, Kawano Y, Kanamaru S, et al. Endogenous interleukin-8 (IL-8) surge in granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization. Blood. 1999;93:1157-1163.
44. Cashen AF, Lazarus HM, Devine SM. Mobilizing stem cells from normal donors: is it possible to improve upon G-CSF? Bone Marrow Transplant. 2007;39:577-588.
45. Ohsaka A, Saionji K, Igari J. Granulocyte colony-stimulating factor administration increases serum concentration of soluble selectins. Br J Haematol. 1998;100:66-69.
46. Arslan Ö, Akan H, Arat M, et al. Soluble adhesion molecules (sICAM-1, sL-Selectin, sE-Selectin, sCD44) in healthy allogenic peripheral stem-cell donors primed with recombinant G-CSF. Cytotherapy. 2000;2:259-265.
47. Arpinati M, Green CL, Heimfeld S, Heuser JE, Anasetti C. Granulocyte-colony stimulating factor mobilizes T helper 2-inducing dendritic cells. Blood. 2000;95:2484-2490.
48. Pulendran B, Banchereau J, Burkeholder S, et al. Flt-3 ligand and granulocyte colony-stimulating factor mobilize distinct human dendritic cell subsets in vivo. J Immunol. 2000;165:566-572.
49. Körbling M, Reuben JM, Gao H, et al. Recombinant human granulocyte-colony-stimulating factor-mobilized and apheresis-collected endothelial progenitor cells: a novel blood cell component for therapeutic vasculogenesis. Transfusion. 2006;46 (10):1795-1802.
50. Allan DS, Dubé P, Busque L, Roy DC. Endothelial-like vascular progenitor cells (VPCs) from allogeneic and autologous donors: mobilization features distinct from hematopoietic progenitors. Biol Blood Marrow Transplant. 2007;13:433-439.
51. Powell TM, Paul JD, Hill JM, et al. Granulocyte colony-stimulating factor mobilizes functional endothelial progenitor cells in patients with coronary artery disease. Arterioscler Thromb Vasc Biol. 2005;25:296-301.
52. Nagler A, Korenstein-Ilan A, Amiel A, Avivi L. Granulocyte colony-stimulating factor generates epigenetic and genetic alterations in lymphocytes of normal volunteer donors of stem cells. Exp Hematol. 2004;32:122-130.
53. Kaplinsky C, Trakhtenbrot L, Hardan I, et al. Tetraploid myeloid cells in donors of peripheral blood stem cells treated with rhG- CSF. Bone Marrow Transplant. 2003;32:31-34.
54. Limpens J, Stad R, Vos C, et al. Lymphoma-associated translocation t(14;18) in blood B cells of normal individuals. Blood. 1995;85:2528-2536.
55. Confer DL, Miller JP. Long-term safety of filgrastim (rhG-CSF) administration. Br J Haematol. 2007;137:77-78 (letter).
56. Pamphilon D, Mackinnon S, Nacheva E, et al. The use of granulocyte colony-stimulating factor in volunteer blood and marrow registry donors. Bone Marrow Transplant. 2006;38:699-700 (letter).
57. Hernandez JM, Castilla C, Gutierrez NC, et al. Mobilization with G-CSF in healthy donors promotes a high but temporal deregulation of genes [letter]. Bone Marrow Transplant. 2006;38:699-700.
58. Amariglio N, Jacob-Hirsch J, Shimoni A, Leiba M, Rechavi G, Nagler AA. Changes in gene expression pattern following granulocyte colony-stimulating factor administration to normal stem cell sibling donors. Acta Haematol. 2007;117:68-73.
59. Shapira MY, Kaspler P, Samuel S, Shoshan S, Or R. Granulocyte colony stimulating factor does not induce long-term DNA instability in healthy peripheral blood stem cell donors. Am J Hematol. 2003;73:33-36.
60. Takamatsu Y, Simmons PJ, Moore RJ, Morris HA, To LB, Lévesque JP. Osteoclast-mediated bone resorption is stimulated during short-term administration of granulocyte colony-stimulating factor but is not responsible for hematopoietic progenitor cell mobilization. Blood. 1998;92:3465-3473.
61. Froberg MK, Garg UC, Stroncek DF, Geis M, McCullough J, Brown DM. Changes in serum osteocalcin and bone-specific alkaline phosphates are associated with bone pain in donors receiving granulocyte-colony-stimulating factor for peripheral blood stem and progenitor cell collection. Transfusion. 1999;39 (4):410-414.
62. Purton LE, Lee MY, Torok-Storb B. Normal human peripheral blood mononuclear cells mobilized with granulocyte colony-stimulating factor have increased osteoclastogenic potential compared to nonmobilized blood. Blood. 1996;87:1802-1808.
63. Fujii K, Ishimaru F, Kozuka T, et al. Elevation of serum hepatocyte growth factor during granulocyte colony-stimulating factor-induced peripheral blood stem cell mobilization. Br J Haematol. 2004;124 (2):190-194.
64. McGuire TR, Kessinger A, Hock L, Sharp JG. Elevated transforming growth factor beta levels in the plasma of cytokine-treated cancer patients and normal allogeneic stem cell donors. Cytotherapy. 2001;3:361-364.